Recent News

• 11.13.2025 - National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
• 11.06.2025 - Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf
• 11.04.2025 - Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results
• 11.04.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 10.14.2025 - Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
• 10.07.2025 - Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
• 09.25.2025 - Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
• 08.26.2025 - National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
• 08.13.2025 - Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
• 08.07.2025 - Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results

Recent Filings

• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.23.2025 - 8-K Current report
• 10.09.2025 - 8-K Current report
• 09.29.2025 - 8-K Current report
• 09.29.2025 - EX-99.1 EX-99.1
• 09.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.26.2025 - 8-K Current report
• 08.29.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]